Rex Bionics
Rex Bionics manufactures REX, a hands-free robotic exoskeleton used by rehabilitation centers and hospitals to provide standing, walking, and exercise therapy for patients with spinal cord injury, multiple sclerosis, stroke, and other neurological conditions causing lower-limb weakness or paralysis.
- Company typePublic
- Founded2007
- HeadquartersAuckland, New Zealand
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Rex Bionics does
Rex Bionics designs, manufactures, and commercializes the REX, a hands-free, self-supporting robotic exoskeleton intended for people with lower-limb weakness or paralysis arising from spinal cord injury, multiple sclerosis, stroke, traumatic brain injury, cerebral palsy, and related neurological conditions. The device is built around ten custom linear actuators supporting users up to 100 kg, a custom carbon-fibre pelvis and cuffs, a rechargeable lithium-polymer battery delivering roughly 60 minutes of use, and a proprietary motion-control stack comprising half a million lines of code distributed across 27 onboard microprocessors. The REX differs from competing exoskeletons (e.g., ReWalk, Ekso) in that it requires no crutches, leaving the user's arms free for upper-body exercise and activities of daily living, and is therefore usable by patients with impaired upper-body function, including tetraplegics and high-level stroke patients.
The company's core commercial offering is the REX hardware sold as a capital purchase to rehabilitation centers, hospitals, and spinal-cord-injury clinics, complemented by the REXERCISES branded set of structured, physiotherapist-designed exercise programs. Rex Bionics operates a direct-sales model with regional offices in Auckland (HQ), Melbourne, and Boston, and distributor partnerships covering China (Maxhealth Medical Group, pending CFDA approval; MAAB Group) and the Middle East (Armana Healthcare). Clinical validation has been pursued through a multi-year trial program including RAPPER II (spinal cord injury, 56 patients), RAPPER III and RAPPER IV (multiple sclerosis, East Kent Hospitals with NIHR), and HELLEN (stroke and brain injury, AIN with University of Newcastle). Reported outcomes include pain reduction from 9/10 to 4/10 'worst pain' in case data, 90% improvement in a 'felt physically tense at night' sleep measure, and 94% of trial volunteers indicating willingness to use REX weekly.
Rex Bionics was incorporated in New Zealand in 2007, previously listed on the AIM market of the London Stock Exchange under ticker RXB (now delisted), and operates through wholly-owned subsidiaries in Australia and the United States. Pricing of the REX device is not publicly disclosed and is handled via direct contact with regional offices; market data for comparable medical exoskeletons places per-unit pricing in the USD 70,000-150,000 range. The company is led by CEO Crispin Simon, with General Manager Tracey White supporting operations and former CEO Dr Charles Carignan having led the firm during earlier clinical-trial phases.
Rex Bionics firmographics
Firmographics- Name
- Rex Bionics
- Legal name
- Rex Bionics Ltd
- Website
- https://rexbionics.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Rex Bionics manufactures REX, a hands-free robotic exoskeleton used by rehabilitation centers and hospitals to provide standing, walking, and exercise therapy for patients with spinal cord injury, multiple sclerosis, stroke, and other neurological conditions causing lower-limb weakness or paralysis.
- Ownership category
- akta.pro rank
Rex Bionics industry classification
Industry- Product category
- Medical Rehabilitation Robotics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Offices of Physical, Occupational and Speech Therapists, and Audiologists (62134)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Healthcare & Assistive Robotics (HDAAAIAC)
- akta.pro secondary industries
- Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG), Prosthetics/Orthotics Rehab & Amputee Rehabilitation (HSADAIAN), Sports & Active Rehabilitation Devices (Adaptive Sports Mobility, Performance Prosthetics) (HLAHAMAJ)
Keywords
Where Rex Bionics is headquartered
LocationHeadquarters
- HQ city
- Auckland
- HQ country
- New Zealand
- HQ region
- Oceania
Offices3 records
Markets served
Rex Bionics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- REX Device Sales: Sale of REX robotic rehabilitation devices to rehabilitation centers, hospitals, and healthcare facilities. The device is a capital purchase requiring significant investment.
- Clinical/Professional Services: Training and support services for healthcare professionals using REX in clinical settings
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | REX Rehabilitation Device |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Rex Bionics product offering
Product offeringCore offering
Rex Bionics designs, manufactures, and sells the REX, a hands-free, self-supporting, independently controlled robotic exoskeleton that enables standing, walking, and structured exercise for people with lower limb weakness or paralysis arising from spinal cord injury, stroke, multiple sclerosis, cerebral palsy, and other neurological conditions. The company sells the REX device primarily to rehabilitation centers, hospitals, and clinical facilities as a capital purchase, complemented by training and clinical support services, with associated structured exercise programs (REXERCISES) developed by specialist physiotherapists.
Product overview
Rex Bionics offers a single unified product portfolio centered on the REX robotic rehabilitation device. The REX is a hands-free exoskeleton that enables standing, walking, and exercise for people with mobility impairments. The companion REXERCISES program provides structured exercise protocols designed by physiotherapists for use within the REX system. The company operates as a medical device manufacturer with operations in New Zealand (headquarters), Australia, USA, and distribution partnerships in China and the Middle East.
Differentiator
Problem solved
Functional benefit
Brands
- REXERCISES: Brand name for the robot-assisted physiotherapy exercise programs developed by Rex Bionics in collaboration with physical therapists
- REX
Products and services
- REX Robotic Rehabilitation Device A hands-free, self-supporting, independently controlled robotic exoskeleton that provides standing, walking, and exercise support for people with lower limb weakness or paralysis, including those with spinal cord injury (complete or incomplete), multiple sclerosis, stroke, cerebral palsy, traumatic brain injury, or other neurological conditions. The device supports users up to 100kg, accommodates users from approximately 4'8" to 6'4" in height, and is sold primarily to rehabilitation centers, hospitals, and clinical facilities as a capital purchase.
Quantifiable outcome
- Six out of eight sleep indicators showed improvement after a single REX treatment in RAPPER II trial
- +4 more outcomes
Companies that use Rex Bionics
Customer profileNamed customers9 records
Segments3 records
Ideal customer profiles2 records
Rex Bionics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Rex Bionics partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered minor and core.
- Chartered Society of Physiotherapists (CSP)minorCSP encouraged participants for the RAPPER IV MS Trial, promoting awareness of the clinical research program.
- East Kent Hospitals University NHS Foundation TrustcorePartnership for RAPPER III and RAPPER IV clinical trials evaluating REX for multiple sclerosis patients. Led by Dr Mohammed Sakel, Director of Neurorehabilitation service. Supported by NIHR (National Institute for Health Research).
- Kent UniversityminorAcademic partnership with East Kent Hospitals for RAPPER III MS clinical trial.
- NHS National Institute for Health Research (NIHR)coreProvided ethics committee approval for RAPPER III clinical trial in multiple sclerosis.
- Australian Institute of Neuro-rehabilitation (AIN)coreConducts clinical trials treating patients who have had a stroke or brain injury with Robot-Assisted Physiotherapy with REX. Ethics clearance through Hunter New England Human Research Ethics Committee. Collaboration with University of Newcastle.
- University of Newcastle, AustraliacoreResearch partner with AIN for stroke and brain injury clinical trials using REX device. Supported by The Newcastle Permanent Charitable Foundation.
- The Newcastle Permanent Charitable FoundationminorFunding support for the HELLEN research trial using REX for stroke and brain injury rehabilitation.
- Maxhealth Medical Group Co. LtdcoreExclusive distributor partnership in China for REX devices. Device not yet available pending approval from CFDA (China Food and Drug Administration). Contact: [email protected]
- MAAB GroupcorePartnership Agreement for China market distribution (mentioned in media section).
- EmergoEuropeminorListed as contact for UK & Europe regulatory/distribution support.
Scale indicators3 records
Recent moves6 records
Expansion highlights7 records
Rex Bionics competitors and assessment
Company assessmentEmerging players
- Bionik Laboratories: Bionik Laboratories develops the InMotion ARM and ARTHUR robotic therapy devices for upper and lower limb rehabilitation in clinical settings. While its product line focuses more on end-effector robotics than full exoskeletons, it competes for the same rehabilitation centre capex budgets that fund REX sales.
- Wandercraft: Wandercraft has developed the Atalante self-balancing lower-limb exoskeleton for stroke and SCI rehabilitation, positioning it as a hands-free alternative in the same way REX does. It represents an emerging peer with overlapping product philosophy in the EU/US rehabilitation market.
Broad incumbents
- Hocoma (part of DIH Medical): Hocoma, now part of DIH Medical, is an established robotic-rehabilitation vendor with Lokomat (gait trainer) and Armeo (upper-limb) products widely used in hospitals. It is a broad incumbent that competes for rehabilitation centre budgets but does not offer a free-standing exoskeleton like REX.
- Honda Walking Assist Device: Honda's Walking Assist Device is a partial lower-limb exoskeleton primarily aimed at gait training in clinical and aged-care settings. It overlaps with REX on the rehab-stance indication and competes with broader incumbents in Japan and parts of Asia.
Direct peers
- Cyberdyne: Cyberdyne's HAL (Hybrid Assistive Limb) is one of the most established lower-limb exoskeletons for rehabilitation and personal use, with strong adoption in Japan and Europe. HAL competes for the same hospital and SCI/Stroke patient indications as REX, though it is also crutch-based.
- Ekso Bionics: Ekso Bionics is a direct competitor in the rehab exoskeleton market with the EksoGT, used in hospitals and rehabilitation centres for stroke and SCI patients. It targets the same B2B clinical channel as Rex Bionics but uses a crutch-based design, making REX's hands-free approach a key point of differentiation.
- ReWalk Robotics: ReWalk is a direct competitor offering both personal and rehabilitation exoskeletons (ReWalk Personal 6.0 and ReStore) for SCI and stroke patients. Like Ekso, ReWalk relies on crutch-based balance, contrasting with REX's hands-free stance; the companies compete directly for hospital capex budgets.
- Parker Hannifin (Indego): Indego, developed by Parker Hannifin, is a modular lower-limb exoskeleton used in rehabilitation centres for SCI and stroke patients in the US. It is a direct competitor to REX in terms of clinical channel, patient indication, and use case.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Rex Bionics social profiles
Digital presenceRex Bionics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rex Bionics leadership team
Management profileNumber of profiles
Profiles2 records
Rex Bionics subsidiaries and ownership
Company hierarchySubsidiaries2 records
Rex Bionics funding detail
Funding detailFunding overview
Funding rounds8 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rex Bionics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rex Bionics
What does Rex Bionics do?
Rex Bionics designs, manufactures, and sells the REX, a hands-free, self-supporting, independently controlled robotic exoskeleton that enables standing, walking, and structured exercise for people with lower limb weakness or paralysis arising from spinal cord injury, stroke, multiple sclerosis, cerebral palsy, and other neurological conditions. The company sells the REX device primarily to rehabilitation centers, hospitals, and clinical facilities as a capital purchase, complemented by training and clinical support services, with associated structured exercise programs (REXERCISES) developed by specialist physiotherapists.
Is Rex Bionics a public or private company?
Rex Bionics is a public company. It is classified as public and is currently operating.
When was Rex Bionics founded?
Rex Bionics was founded in 2007. It employs 11 to 50 people.
Where is Rex Bionics based?
Rex Bionics is headquartered in Auckland, New Zealand, in the Oceania region.
How does Rex Bionics make money?
Two revenue lines are on record. REX Device Sales are the primary driver. The others are clinical/Professional Services.
Who are Rex Bionics's main competitors?
Emerging players on record are Bionik Laboratories and Wandercraft. Broad incumbents are Hocoma (part of DIH Medical) and Honda Walking Assist Device. Direct peers are Cyberdyne, Ekso Bionics, ReWalk Robotics and Parker Hannifin (Indego).
Does Rex Bionics have an API?
No public API is recorded for Rex Bionics.
What industry is Rex Bionics in?
Rex Bionics's product category is Medical Rehabilitation Robotics. Its primary akta.pro industry code is HDAAAIAC, Healthcare & Assistive Robotics, with a secondary code of HLAHAMAG, Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices). Its NAICS code is 334510 and its SIC code is 3842.